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Objective. To investigate the association between type 2 diabetes, glucose-lowering therapies (monotherapy with either metformin,
sulphonylurea or insulin) and cancer risk in Taiwan. Methods. Using Taiwan’s National Health Research Institutes database of
1,000,000 random subjects from 2000–2008, we found 61777 patients with type 2 diabetes (age ≥20 years) and 677378 enrollees
with no record of diabetes. Results. After adjusting for age and sex, we found patients with diabetes to have signiﬁcantly higher risk
of all cancers (OR: 1.176; 95% CI: 1.149–1.204, P<0.001). Diabetic patients treated with insulin or sulfonylureas had signiﬁcantly
higher risk of all cancers, compared to those treated with metformin (OR: 1.583; 95% CI: 1.389–1.805, P<0.001 and OR: 1.784;
95% CI: 1.406–2.262, P<0.001). Metformin treatment was associated with a decreased risk of colon and liver cancer compared
to sulphonylureas or insulin treatment. Sulfonylureas treatment was associated with an increased risk of breast and lung cancer
compared to metformin therapy. Conclusions. Taiwanese with type 2 diabetes are at a high risk of breast, prostate, colon, lung, liver
and pancreatic cancer. Those treated with insulin or sulfonylureas monotherapy are more likely to develop colon and liver cancer
than those treated with metformin.
1.Introduction
CancerhasbecometheleadingcauseofdeathinTaiwansince
1982 [1]. Tseng [2] reported cancer to be the second leading
cause of mortality in patients with type 2 diabetes in Taiwan.
Patients with type 2 diabetes are known to be at increased
risk of cancer and cancer mortality [3–9], especially hepatic
[3]p a n c r e a t i c[ 6], colon [8], bladder [9–11], and breast
cancer [5, 12]. The relationship between type 2 diabetes
and cancer is complex, possibly involving insulin resistance,
hyperinsulinemia, and elevated levels of insulin-like growth
factor-1 (IGF-1) in tumor cell growth [13, 14].
Glucose-lowering therapy may also play a role in the
relationship between type 2 diabetes and cancer. Metformin
treatment might reduce the risk of tumor development [15–
20], whereas insulin and sulphonylureas might increase the
risk [21, 22]. This study used Taiwan’s National Health
Insurance claims database to investigate the relationship
between type 2 diabetes, glucose-lowering therapy with
either metformin, sulphonylureas, or insulin alone, and
cancer in the Taiwanese.
2. Methods
2.1.DataSources. Taiwan’sNationalHealthInsurance(NHI)
medical claims database, including ambulatory care, hospital
inpatient care, dental services, and prescription drugs, was
provided by Taiwan’s National Health Research Institutes
(NHRI). NHI coverage rate was 96.16% of the whole
population in 2000 and rose to 99% by the end of 2004.
The data set used for this study was a randomly sampled
cohort of 1 million individuals enrolled in the NHI system2 Experimental Diabetes Research
from 2000 to 2008. It included information on registration
entries, ambulatory care claims, inpatient care claims, and
prescription. Patient identiﬁcation numbers were scrambled
for protection of conﬁdentiality, and hence no ethics board
approval was needed.
NHI diagnosis coding follows the International Classiﬁ-
cation of Diseases, Ninth Revision (ICD-9), Clinical Modiﬁ-
cation diagnostic criteria. Records of claims for diabetes care
were collected for patients with diabetes-related diagnosis
with ICD-9 code 250 (excluding type 1 diabetes with ICD-9
code 250.1). An individual was classiﬁed as a diabetic patient
if she or he had an initial diabetes-related diagnosis at any
time in 2000 and then had at least one service claim from
either ambulatory or inpatient care within the subsequent
twelve months. Focusing on newly diagnosed cancer cases,
we excluded patients diagnosed for any type of cancer (ICD-
9: 140–209, 230–239) before the ﬁrst year of the study period
(2000-2001). The end of study period for each enrollee, both
diabetic and nondiabetic, was, if any, ﬁrst episode of primary
or secondary diagnosis of any types of cancer from 2002 to
2008.
The previous studies revealed that metformin treatment
[15–20] might reduce the risk of tumor development and
insulin and sulphonylurea [21, 22] might increase it. Our
study wanted to clarify the inﬂuence of these antidiabetic
agents (metformin, insulin, and sulphonylurea) on cancer
risk in Taiwanese. To investigate the association between
antidiabetic agents (monotherapy with either metformin,
sulphonylurea, or insulin) and incident cancer, we included
only type 2 diabetic patients receiving monotherapy with
either metformin, sulphonylurea, or insulin. The kind of
insulin included intermediate/long acting human insulin
(HI), insulin glargine, insulin detemir, fast acting HI and
insulin analogues, and premix HI and insulin analogues. The
kind of sulphonylurea included glibenclamide, gliclazide,
glipizide, and glimepiride. These patients had to have
received continuous drug coverage for at least one year
during study period and have no prior diagnosis of cancer.
We excluded patients who were diagnosed as having cancer
before the time they were prescribed antidiabetic drugs
during the study period. The male patients were excluded
from our analysis of breast cancer, and the female patients
from our analysis of prostate cancer.
2.2. Statistical Analysis. The risk of type 2 diabetes on
cancers was tested by logistic regression models with age
and sex adjustment. To determine the independent eﬀects
of antidiabetic drugs on the risk of any types of cancers, we
used logistic regression models with age and sex adjustment.
Breast cancer and prostate cancer were only adjusted for age
but not sex. All statistical operations were performed using
SAS version 9.2. A P-value of less than 0.05 was considered
signiﬁcant.
3. Results
In total, 61777 patients with type 2 diabetes (mean age
61.44 ± 13.23 years; 51.1% male) were followed up from
Table 1: Adjusted odds ratios and 95% conﬁdence intervals for all
cancers associated with type 2 diabetes, sex, and age.
Covariate Adjusted
odds ratio 95% CI P value
Type 2 diabetes (versus
nondiabetic subjects) 1.176 1.149–1.204 <0.001
Sex (female versus male) 1.293 1.273–1.313 <0.001
Age (every 1-yr increment) 1.040 1.039–1.040 <0.001
2000 to 2008. Patients with type 2 diabetes were found to
be at a signiﬁcantly higher risk of all cancers (odds ratio
(OR): 1.176; 95%, conﬁdence interval (CI): 1.149–1.204, P<
0.001) after adjusting for sex and age while compared to
nondiabetic subjects (Table 1). Female and elderly subjects
were at a signiﬁcantly higher risk of all cancers than their
male and younger counterparts (OR: 1.293, 95% CI: 1.273–
1.313, P<0.001 and OR: 1.040, 95% CI: 1.039–1.040, P<
0.001, resp.).
As can be seen in Table 2, a summary of incident
cases of diﬀerent types of cancer in patients with and
without diabetes, patients with type 2 diabetes were at
signiﬁcantly higher risk of breast cancer, prostate cancer,
colon cancer, lung cancer, liver cancer, and pancreatic cancer
after adjusting for sex and age as compared to nondiabetic
subjects.
A total of 10189 patients with type 2 diabetes (mean age
61.18 ± 14.03 years; 52.2% male) were identiﬁed as receiv-
ing monotherapy of insulin, sulfonylureas, or metformin.
Patients receiving insulin or sulfonylurea had a higher risk
of all cancers, compared to those receiving metformin (OR:
1.583, 95% CI: 1.389–1.805, P<0.001 and OR: 1.784, 95%
CI: 1.406–2.262, P<0.001, resp.), after adjusting for sex
and age (Table 3). Female patients with type 2 diabetes were
at a signiﬁcantly lower risk of all cancers than the male
patients with type 2 diabetes (OR: 0.777, 95% CI: 0.692–
0.873, P<0.001). Elderly patients with type 2 diabetes were
at a signiﬁcantly higher risk of all cancers (OR: 1.037, 95%
CI: 1.033–1.042, P<0.001) as compared to younger patients
with type 2 diabetes.
Table 4 shows the adjusted odds ratios for speciﬁc
cancers associated with antidiabetic drugs. Patients receiving
insulin or sulphonylureas had a higher risk of colorectal
and liver cancers compared to those receiving metformin
after adjusting sex and age. Sulphonylureas were additionally
associated with an increased risk of breast and lung cancer.
We found no relationship between glucose-lowering therapy
and prostate, esophageal, gastric, or pancreatic cancer.
4. Discussion
Our study demonstrates that Taiwanese with type 2 diabetes
are at a high risk of cancer, especially breast, prostate, colon,
lung, liver, and pancreatic cancer compared to nondiabetic
subjects (Tables 1 and 2). Among diabetic patients, those
receiving insulin or sulphonylurea monotherapy are at a
higher risk of cancer compared to those receiving metformin
(Table 3). Patients treated with metformin are at a lower riskExperimental Diabetes Research 3
Table 2: Adjusted odds ratios and 95% conﬁdence intervals for speciﬁc types of cancer associated with type 2 diabetes.
Site-speciﬁc cancer Patients with type 2 diabetes Subjects without diabetes Adjusted odds ratio P value
(n = 61777) (n = 677378) (95% CI)
Cases % Cases %
Breast 665 2.20 4042 1.16 1.111 (1.018–1.212) 0.018
Prostate 587 1.86 2223 0.68 1.137 (1.036–1.249) 0.007
Colon 1739 1.98 7219 1.07 1.206 (1.142–1.274) <0.001
Lung 1226 2.81 4281 0.63 1.296 (1.214–1.384) <0.001
Liver 1528 2.47 5558 0.82 1.582 (1.491–1.680) <0.001
Stomach 523 0.85 2700 0.40 0.920 (0.836–1.012) 0.088
Pancreas 286 0.46 731 0.11 2.038 (1.768–2.349) <0.001
Subjects without diabetes as reference and adjustment for sex and age.
Table 3: Adjusted odds ratios and 95% conﬁdence intervals for all
cancers associated with antidiabetic drugs, sex, and age in type 2
diabetic patients treated with metformin, sulfonylurea, or insulin
monotherapy.
Covariate Adjusted
odds ratio 95% CI P value
Antidiabetic drugs
Sulfonylurea versus
metformin 1.784 1.406–2.262 <0.001
Insulin versus
metformin 1.583 1.389–1.805 <0.001
Sex (female versus male) 0.777 0.692–0.873 <0.001
Age (every 1-yr increment) 1.037 1.033–1.042 <0.001
of colorectal and liver cancers, compared to those receiving
either insulin or sulphonylurea (Table 4), and at a lower
risk of breast and lung cancer (Table 4), compared to those
receiving sulphonylureas.
Type 2 diabetes has already been linked to an increased
risk of cancer [3–12]. One meta-analysis [5] found the
relative risk (RR) of breast cancer to be 1.20 for women with
diabetes compared to women without diabetes. Three meta-
analyses found RR of colon, pancreatic, and hepatocellular
cancer in diabetic patients to be 1.30 [8], 1.82 [6], and
1.84 [3], compared to nondiabetic subjects. However, the
incidence rates of type 2 diabetes and cancer vary widely
across populations. The current study found people with
diabetes in Taiwan to be at a high risk of all cancers (odds-
ratio (OR): 1.176; 95%, conﬁdence interval (CI): 1.149–
1.204, P<0.001), especially breast, colon, liver, lung,
prostate, and pancreatic cancers (Table 2). Recently, Lee et al.
[23]alsoreportedpatientswithdiabetestobeatahighriskof
liver, colon, lung, and prostate cancer. Our study found that
patients with type 2 diabetes were not at high risk of gastric
cancer (Table 2). Recently, Tseng [24] reported that diabetic
Taiwanese have a higher risk of gastric cancer mortality. It
should be pointed out that overall incidence of gastric cancer
and mortality from the disease are two diﬀerent entities and
probably linked to diﬀerent factors.
Previous studies [25–28] have shown that cancer inci-
dence is much higher in males than females at nearly
all ages. Our study revealed that female Taiwanese have
higher incidence of cancers as compared to male subjects
in the general population (Table 1). However, we found that
female diabetic patients have lower incidence of cancers
as compared to male diabetic patients (Table 3). The sex
disparities in cancer incidence might be due to illness behav-
ior, health care access and utilization and ethnic diﬀerence
[29, 30]. Future epidemiologic studies should be encouraged
to design, analyze, and report sex-speciﬁc associations to aid
the understanding of sex diﬀerences in cancer incidence in
Taiwanese.
The association between diabetes and cancer may be
mediated by metabolic syndrome and obesity through
hyperinsulinemia and insulin resistance. Insulin is a growth
hormone and is known to have atherogenic and mitogenic
properties [31–33]. One observational study showing a
relationship between level of circulating insulin and cancer
has suggested that cancer growth may be inﬂuenced by the
insulin-IGF-1 signaling axis [34].
This study found male Taiwanese with diabetes to
be at a higher risk of prostate cancer than nondiabetic
subjects (OR: 1.137, 95% CI: 1.036–1.249, P = 0.007,
Table 2). This is inconsistent with Tseng’s ﬁnding of a
positive association between diabetes and prostate cancer
in Taiwan, an association that became more remarkable
in the younger patients [35]. However, previous studies of
populations with European ancestries [36, 37]h a v er e p o r t e d
men with diabetes to have a 20% lower risk of developing
prostate cancer than men without diabetes. Two large-
scale population-based cohort studies in Japan [38, 39]
found no relationship between diabetes and prostate cancer,
and one recent study [40] has suggested that diabetes is
a protective factor for prostate cancer across populations,
including Japanese Americans. The possible reasons for
these inconsistent results may be ethnic and environment
factors, screening frequency of prostate cancer, and the use
of prostate speciﬁc antigen.
Our study also found that diabetic Taiwanese were at
a high risk of lung cancer (OR: 1.296, 95% CI: 1.214–
1.384, P<0.001, Table 2). Coughlin et al. [4]r e p o r t e d
diabetic men as well as women to be at a higher risk of lung
cancer in the US. Jee et al. [41], studying UK population,
also found slightly higher but insigniﬁcant risk of lung
cancer for men and signiﬁcantly higher risk for women,4 Experimental Diabetes Research
Table 4: Adjusted odds ratios and 95% conﬁdence intervals for speciﬁc cancers associated with antidiabetic drugs.
Site-speciﬁc cancer
Metformin Sulfonylurea Insulin Age-sex-adjusted odds ratio Age-sex-adjusted odds ratio
(n = 3963) (n = 6072) (n = 751) (95% CI) (95% CI)
Cases/n % Cases/n % Cases/n % Insulin versus metformin Sulfonylureas versus metformin
Breast∗ 19/2048 0.93 48/2804 1.71 5/338 1.48 1.630 (0.604–4.396) 1.765 (1.030–3.024)
Prostate∗ 27/1915 1.41 52/3268 1.59 5/413 1.21 0.893 (0.338–2.359) 1.034 (0.644–1.659)
Colon and rectum 46/3963 1.16 145/6072 2.39 18/751 2.40 2.135 (1.226–3.717) 1.847 (1.320–2.585)
Lung 45/3963 1.14 122/6072 2.01 9/751 1.20 1.058 (0.513–2.183) 1.570 (1.110–2.220)
Liver 58/3963 1.46 143/6072 2.36 19/751 2.53 1.818 (1.075–3.077) 1.504 (1.104–2.049)
Stomach 20/3963 0.50 54/6072 0.89 7/751 0.93 1.855 (0.779–4.419) 1.547 (0.923–2.594)
Pancreas 8/3963 0.20 21/6072 0.35 1/751 0.13 0.693 (0.087–5.545) 1.594 (0.705–3.619)
∗Breast cancer and prostate cancer were only adjusted for age but not sex.
after adjusting for age, age squared, smoking, and drinking.
Some cohort studies, however, have reported a negative
association between diabetes and lung cancer [42–44]. Given
these inconsistent ﬁndings, further prospective studies are
needed to conﬁrm the relationship between type 2 diabetes
and speciﬁc cancers in diﬀerent ethnic populations.
Our study found that diabetic patients treated with
sulphonylurea or insulin monotherapy were at a signiﬁcantly
higher risk of cancers, compared to those treated with
metformin. Likewise, Currie et al. [45] have also found
diabetic patients on insulin or insulin secretagogues to
be more likely to develop solid cancers than those on
metformin. Bowker et al. [46] reported that patients with
type2diabetestreatedwithsulphonylureasandinsulinareat
signiﬁcantly increased risk of cancer-related mortality than
those treated with metformin. Our ﬁnding that not only
treatmentwithinsulinbutalsotreatmentwithsulphonylurea
increased the risk seems to exclude an adverse property
of the insulin formulation itself. Our study revealed that
there was no signiﬁcant association between antidiabetic
agents (monotherapy with either metformin, sulphonylurea,
or insulin) and prostate cancer in Taiwanese with type
2 diabetes. Tseng [47] also reported that insulin use is
not signiﬁcantly predictive for prostate cancer mortality in
diabetic Taiwanese. Recently, Lai et al. [48] also reported
that the use of metformin would decrease the risk of lung
cancer in Taiwanese with diabetes. Taken together, these
studies strongly suggest that glucose-lowering agents may
play a role in the relationship between type 2 diabetes and
some cancers. How they do this remains unclear. Metformin
decreases insulin resistance and may thus possibly reduce the
risk of cancer. It might also directly act on AMP-activated
protein kinase (AMPK) signaling pathway [17].
Compared to those treated with sulphonylureas or
insulin, diabetic patients treated with metformin had a
signiﬁcantly lower risk of developing colorectal and liver
cancers (Table 4). Currie et al. [45] also found an association
between metformin use and a lower risk of colon cancer. We
further revealed that metformin was associated with a lower
risk of breast and lung cancer, compared to sulphonylureas
(Table 4). These ﬁndings suggest that metformin may have
anticancer eﬀects, suﬃcient to justify its use as a ﬁrst-line
treatment for diabetes and its potential use outside the
context of diabetes.
This study has several limitations. First, it is subject
to many limitations inherent to all observational studies.
We lacked information on potentially important clinical
covariates, such as smoking status, weight or body mass
index, glycemic control, and alcohol consumption. Second,
patients might be prescribed diﬀerent treatment regimens
for health-related reasons. Third, there were relatively small
numbers of some speciﬁc cancers in patients with diﬀerent
glucose-lowering therapy, thereby limiting the power of our
analysis.
In conclusion, type 2 diabetes is a risk factor for cancer
in the Taiwanese. Metformin use was associated with a lower
risk of cancer of the colon and liver, two common cancers
in Taiwan. Further prospective studies are needed to conﬁrm
this relationship and study the possible mechanisms between
cancers and antidiabetic drugs in Taiwan.
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